Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
Status:
Recruiting
Trial end date:
2022-06-21
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared
with placebo in episodic migraines in participants who previously failed 2 to 4 classes of
oral prophylactic treatments.